Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Keros Therapeutics (KROS)
NASDAQ:KROS
Holding KROS?
Track your performance easily
KROS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$27.02 - $73.00
Previous Close$55.71
Volume393.95K
Average Volume (3M)358.77K
Market Cap
$2.09B
Enterprise Value$1.70B
Total Cash (Recent Filing)$405.90M
Total Debt (Recent Filing)$13.96M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Oct 31, 2024EPS Estimate
-$1.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.13
Shares Outstanding37,522,097
10 Day Avg. Volume369,140
30 Day Avg. Volume358,773
Standard Deviation0.21
R-Squared0.08
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)4.96
Price to Sales (P/S)7620.72
Price to Cash Flow (P/CF)-13.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.27K
Enterprise Value/Gross Profit11.25K
Enterprise Value/Ebitda-13.48
Forecast
1Y Price Target
$103.50Price Target Upside80.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Keros Therapeutics News
PremiumCompany Announcements
Keros Therapeutics CEO to Speak at Major Healthcare Conferences
PremiumCompany Announcements
Keros Therapeutics Updates Investors with New PresentationBulls Say, Bears Say
Bulls Say
Clinical TrialsCibotercept’s phase 2 TROPOS (PAH) enrolling faster than expected has led to positive momentum likely to continue heading into updates from the elritercept MDS and MF phase 2s.
Pipeline DevelopmentLonger term, underappreciated upside is seen for phase 1 obesity and neuromuscular candidate KER-065, with potential further momentum for shares expected from healthy volunteer data.
Product UptakeMerck recently reported uptake of Winrevair has been robust, with success converting prescriptions into patients on therapy, which offers support for cibotercept.
Bears Say
Clinical TrialsThe planned Phase 2 open-label biomarker study in chronic heart failure has been terminated prior to enrolling any patients.
Comparative EfficacyIt will likely take more data for KER-050 to look persuasively better than luspatercept in the high unmet need subset.
Safety ConcernsDespite its favorable label, bleeding risks are still a concern for cibotercept, according to key opinion leaders.
---
Ownership Overview
23.70% Insiders
23.00% Mutual Funds
49.03% Other Institutional Investors
4.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KROS FAQ
What was Keros Therapeutics’s price range in the past 12 months?
Keros Therapeutics lowest stock price was $27.02 and its highest was $73.00 in the past 12 months.
What is Keros Therapeutics’s market cap?
Currently, no data Available
When is Keros Therapeutics’s upcoming earnings report date?
Keros Therapeutics’s upcoming earnings report date is Oct 31, 2024 which is in 41 days.
How were Keros Therapeutics’s earnings last quarter?
Keros Therapeutics released its earnings results on Aug 07, 2024. The company reported -$1.25 earnings per share for the quarter, beating the consensus estimate of -$1.258 by $0.008.
Is Keros Therapeutics overvalued?
According to Wall Street analysts Keros Therapeutics’s price is currently Undervalued.
Does Keros Therapeutics pay dividends?
Keros Therapeutics does not currently pay dividends.
What is Keros Therapeutics’s EPS estimate?
Keros Therapeutics’s EPS estimate is -$1.27.
How many shares outstanding does Keros Therapeutics have?
Keros Therapeutics has 37,522,100 shares outstanding.
What happened to Keros Therapeutics’s price movement after its last earnings report?
Keros Therapeutics reported an EPS of -$1.25 in its last earnings report, beating expectations of -$1.258. Following the earnings report the stock price went down -2.181%.
Which hedge fund is a major shareholder of Keros Therapeutics?
Among the largest hedge funds holding Keros Therapeutics’s share is Woodline Partners LP. It holds Keros Therapeutics’s shares valued at 35M.
---
Keros Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$103.50 (80.57% Upside)
$103.50 (80.57% Upside)
Blogger Sentiment
Bullish
KROS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 277.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $22.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
56.84%
12-Months-Change
Fundamentals
Return on Equity
-44.98%
Trailing 12-Months
Asset Growth
27.71%
Trailing 12-Months
Company Description
Keros Therapeutics
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
---
KROS Stock 12 Month Forecast
Average Price Target
$103.50
▲(80.57% Upside)
Technical Analysis
Allogene Therapeutics
―
Crispr Therapeutics AG
―
Fate Therapeutics
―
Intellia Therapeutics
―
Best Analysts Covering KROS
1 Year
1 Year Success Rate
9/14 ratings generated profit
1 Year Average Return
+18.84%
reiterated a buy rating 3 months ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +18.84% per trade.
---